Despite the reported decline in the incidence and death rate from gastric cancer throughout the world (Day, 1980) , it will remain a major clinical problem for the foreseeable future. Surgery has formed the main treatment for gastric cancer and, as in many solid tumours, salvage therapy for unresectable or recurrent disease has failed to influence survival. The Japanese have reported improved results for surgical treatment of gastric cancer (Miwa, 1979) , using strict rules for surgery and pathological examination (Japanese Research Society for Gastric Cancer 1981). In the West, however, there has been almost no progress in the management of this condition in recent years, and this has led to a fatalistic attitude to treatment among many clinicians. The work from Japan has demonstrated that progress is possible and has shown the importance of careful documentation and auditing both to establish the best form of surgery and to assess the value of any adjuvant treatment.
The British Stomach Cancer Group (BSCG) designed a prospective, randomised controlled trial to compare surgery alone with surgery and adjuvant radiotherapy or surgery and adjuvant chemotherapy in operable disease. The protocol emphasised detailed recording of surgical procedures together with full documentation and thorough review of the resected specimen in order to stage disease accurately. The chemotherapy regimen comprised 5-fluorouracil (5-FU), adriamycin and mitomycin C, a combination which in studies of advanced disease has produced a 42% response rate (MacDonald et al., 1980) and gave a 37% response rate in a pilot study of the BSCG variant (MAF) (P.F.M. Wrigley; personal communication).
The incorporation of adjuvant radiotherapy was based on evidence from autopsy and re-operation series which has consistently demonstrated that the stomach bed and regional nodes were the most common sites of failure either alone or in combination with distant metastases (McNeer et al., 1951; Gunderson & Sosin, 1982) . Furthermore, in selected patients modest doses of megavoltage irradiation has improved survival at 2 years when compared with a control group undergoing gastric resection only (Robinson & Cohen, 1977) .
Recruitment to this trial was completed between June 1981 and July 1986. This report describes the details of this trial and evaluates the initial results.
Materials and methods
A prospective, randomised controlled trial of adjuvant chemotherapy and radiotherapy following gastric resection for adenocarcinoma recruited patients from 10 centres throughout the United Kingdom. Participating centres were the West Midlands, London, Manchester, Airedale, York, Bristol, Swansea, Sunderland, Leeds and Edinburgh.
Patients eligible for entry to the trial were aged between 15 and 74 years and had undergone surgical resection for adenocarcinoma of the stomach. Patients were staged using a clinicopathological system (Table I ). All patients entered into the study gave informed consent.
Those cases excluded were stage I, IVAii or IVB disease, those who had previous significant malignant disease or prior cytotoxic or radiation therapy. In addition, patients were excluded from randomisation where there was any intestinal or biliary obstruction (unrelieved by surgery), impaired renal function (blood urea greater than 9 mmol 1' or serum creatinine greater than 120 mmol I'), or concurrent cardiac failure.
Before randomisation patients were stratified by centre according to age (younger than 60 years or 60 years and over), length of history (less than 6 months and 6 months or longer) and stage of disease.
Randomisation was into one of three treatment groups: surgery alone, surgery and radiotherapy to the tumour bed The chemotherapy regimen consisted of mitomycin C 4 mg m-2, adriamycin 30 mg m-2 and 5-fluorouracil 600mg m2 given intravenously on one day only (MAF).
The first course was to be administered within 4 weeks of surgery and repeated at 3-weekly intervals for a total of eight courses. Dosages were modified according to haematological and biochemical parameters including urinalysis for proteinuria. Half doses were given if the white blood cell count was in the range 2.0-3.0 x 1091' or the platelet count was 100-125 x 109 1-'. If the counts were below the lower limits of these ranges, no drugs were given and blood counts were checked weekly until adequate levels returned. Proteinuria on two successive occasions or a rise in blood urea to 8 mmol 1' or serum creatinine to 150 mmol 1' were indications to stop administration of mitomycin C.
Patients randomised to radiotherapy were required to undergo intravenous pyelography, and be planned on either a simulator or a diagnostic X-ray unit. Radiotherapy was administered using AP/PA parallel opposed portals to include the porta hepatis and splenic hilum as marked at surgery.
Appropriate renal shielding was employed to exclude as much renal tissue from the treatment field as possible. A mid line tumour dose of 4,500 cGy in 25 fractions over 35 days was given using megavoltage equipment (cobalt-60 or linear accelerator). A further boost dose of 500cGy to a reduced field could be given at the discretion of the radiotherapist.
Blood counts were monitored weekly throughout treatment.
All patients were to be seen every 3 weeks for the first 6 months after surgery. Thereafter follow-up was to be every 6 weeks for 2 years and subsequently at 3-monthly intervals. At each visit data sheets were completed to document clinical progress, including evidence of recurrence. Haematological and biochemical parameters were recorded together with details of any side-effects from treatment. Clinicians were requested to provide post mortem evidence of disease status at death whenever possible. Survival has been taken as the only criterion of response. In addition to the clinical follow-up within the trial, the completeness of the notification of death was verified by the registration of patients with the West Midlands Regional Cancer Registry. All randomised patients were included in the survival analysis. The survival of live patients was censored at I July 1987 when all had complete follow-up. The probability of survival has been estimated by the life-table method (Kaplan & Meier, 1958) and statistical comparisions made with the log rank test (Peto et al., 1977) .
Results

Patients
During the 5 years of recruitment 436 patients were entered into the study. The data were analysed when there was a minimum follow-up of 12 months. After randomisation there were 145 in the surgery only group, 153 in the radiotherapy group and 138 in the chemotherapy group. The distribution of patient characteristics within each treatment group is shown in Table II. After completion of recruitment, the eligibility of all patients was assessed according to the protocol criteria for inclusion in the trial. Details of the 25 entry criteria violations found are shown in Table III .
Six patients died within 30 days of operation. Three died of their disease, one of a myocardial infarct and two of complications of surgery. All had already been randomised, to surgery alone (one patient), radiotherapy (two patients) and chemotherapy (three patients).
Randomisation was achieved within a month of operation in 409 (95%) of the 436 patients entered. The median time to randomisation was 13 days with a range of 1-82 days. The time from operation to start of treatment varied with the treatment drawn. The 145 patients in the surgery group were placed on routine review with 49 (34%) being seen in the first month and 66 (46%) being seen in the second. For the 153 patients randomised to radiotherapy 31 (20%) began radiotherapy within 1 month of operation and 60 (39%) within the second. By comparision 74 (54%) of the 138 randomised to chemotherapy were treated in the first month and 37 (27%) in the second. Treatment commenced within a month of operation in 105 (45%) of the 232 cases who received adjuvant therapy. Treatment Chemotherapy The number of cycles given to each of the 138 patients randomised to receive chemotherapy is shown in Table IV . Twenty-three (17%) patients did not receive chemotherapy. They either refused (11 patients), were too ill or had died (9 patients) or had pre-existing cardiac disease (2 patients). In one case the reason is not known.
Thirty patients (22%) received less than six cycles of chemotherapy. In this group, progressive ill health (13 patients) and refusal (12 patients) were the major reasons for stopping. The remaining indications were debilitating vomiting and nausea (3 patients), haematological and biochemical toxicity (I patients) and hypotension (1 patient).
Eight-five (62%) of the 138 patients completed six or more cycles with 58 (42%) completing the planned eight cycles. In the 27 patients having six to seven cycles, seven patients became too unwell and two refused to continue the final cycles. Side-effects halting treatment were haematological and biochemical toxicity (7 patients), debilitating nausea and vomiting (2 patients) and allergy to one of the agents (6 patients). Hypotension caused one patient to stop and in two patients the reason for failure to complete the treatment programme is not known.
The indications for the modification of chemotherapy have already been described. Of the 115 who started treatment, 75 completed their given cycles without dose modification. The commonest reasons for modification were haematological changes (19 patients) and evidence of renal dysfunction (10 patients). The remaining reasons and cycle at which dose modifications were made are shown in Table V 
Effect of treatment
The three treatment groups do not differ significantly in their survival (Figure 2 ; X22 = 5.3, P = 0.07). or both (Table VI) . These data, though based on clinical findings, show a lower local and regional relapse rate in those receiving adjuvant treatment (X2 = 10.7, P<0.01). Cause of death At the time of analysis 334 (77%) of the patients admitted to the trial had died, 1 10 in the surgery alone group, 123 in the radiotherapy group and 101 in the chemotherapy group. The cause of death (Table VII) has been obtained from the clinican in charge of the case, general practitioners or from cancer registries. Autopsies were performed on 35 (11%).
Two hundred and ninety-two deaths were due to recurrent stomach cancer. Other causes were responsible for the death of 37 patients. Seven patients died from other primary cancers, of which three were bronchogenic, and one each of melanoma, larynx, prostate and colon. Fourteen deaths were secondary to cardiovascular or cerebrovascular disease. This group includes seven acute myocardial deaths, six of which occurred in the radiotherapy group. General deterioration in health caused 10 deaths. Six patients died as a result of surgical complications, one of which followed a second gastric resection for recurrent disease. The cause of death is not known in five cases.
In summary, 37 patients are known to have died from M S R 72 Months causes other than gastric cancer, eight of whom were randomised to surgery alone, 18 to radiotherapy and 11 to chemotherapy. This difference in the proportion of noncancer deaths between the three treatment groups is not statistically significant (X2 = 3.5, 0.1 <P < 0.2).
Discussion
The study described in this report was set up to evaluate the role of two modalities of adjuvant treatment in advanced gastric cancinoma. The trial was designed to incorporate the detailed documentation recommended by Japanese workers and was extended to include a central pathology review. A detailed record of the surgical procedures undertaken in each patient was made and all histological specimens obtained at operation were subjected to thorough review to ensure consistent pathological grading and staging. The adjuvant treatments assessed were short-term chemotherapy using the most effective agents in combination and local radiotherapy to the tumour bed. In this interim report the results of recruitment, randomisation and the therapeutic regimens have been presented. The clinicopathological data will form the subject of a future report.
The cytotoxic agents evaluated in this study have been reported to have produced the best response rates seen in the treatment of advanced or recurrent gastric cancer (Earl et al., 1984) . There (Cunningham et al., 1984) . (Schein et al., 1986) . It remains to be seen whether this advantage will persist.
There have been reports of complete responses to radiotherapy given as palliation for advanced disease (Gunderson & O'Connell, 1984; Weiland & Hymmen, 1970) , though these are rare. The difficulties in the use of radiotherapy in the treatment of gastric cancer stem from the sensitivity of the surrounding structures which limit the dose that can be used (Gunderson, 1986) . Studies have demonstrated that the sites of local failure can be encompassed in a conventional radiotherapy field (Gunderson & Sosin, 1982 (Fielding et al., 1983 
